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Abstract: Lipids comprise diverse classes of compounds that are important for the structure and
properties of membranes, as high-energy fuel sources and as signaling molecules. Therefore, the
turnover rates of these varied classes of lipids are fundamental to cellular function. However, their
enormous chemical diversity and dynamic range in cells makes detailed analysis very complex.
Furthermore, although stable isotope tracers enable the determination of synthesis and degradation
of complex lipids, the numbers of distinguishable molecules increase enormously, which exacerbates
the problem. Although LC-MS-MS (Liquid Chromatography-Tandem Mass Spectrometry) is the
standard for lipidomics, NMR can add value in global lipid analysis and isotopomer distributions of
intact lipids. Here, we describe new developments in NMR analysis for assessing global lipid content
and isotopic enrichment of mixtures of complex lipids for two cell lines (PC3 and UMUC3) using
both 13C6 glucose and 13C5 glutamine tracers.
Keywords: stable isotope tracers; Nuclear Magnetic Resonance; lipid 13C incorporation; isotopomer
distributions
1. Introduction
Lipids comprise an extremely diverse group of compounds that have a wide range
of biological functions from structure (e.g., membranes) to signaling molecules. Even
discounting all the many ways in which they form complexes with other molecules, lipids
come in an enormous diversity of forms [1,2]. These range from fatty acids as short as
acetate (n = 2) to palmitic acid, the end product of fatty acid synthase activity (n = 16), to
longer chain fatty acids such as arachidonic acids (n = 24), which are incorporated into
complex lipids via esterification to a variety of headgroups (Figure S1, Scheme S1). The
natural fatty acids may be saturated or have different numbers of double bonds in different
positions, and may have either odd or even chain lengths, and in some cases branched
chains. A completely separate and diverse branch of lipids also based on acetate is the
steroids, which include cholesterol, and their metabolic products, the bile acids. Complex
lipids comprise compounds that contain 1–3 fatty acyl chains linked to a short backbone
group such as glycerol, which is further esterified to a wide range of head groups. Even for
glycerophospholipids with 6 different headgroups and 20 fatty acids, there are thousands of
possible lipids (many of which do not occur naturally) [Figure S1]. A significant number of
the lipids are also isomers, further complicating analysis, and which is only partly resolved
by tandem MS at a very high resolution [3]. It has been estimated that there are more than
1000 natural lipid species present in a eukaryotic cell [4], and all organisms either synthesize
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them de novo or acquire them from the diet [5]. In mammals, there are a few essential
fatty acids such as linoleic and α-linolenic acid, but there are also many lipids present that
are of exogenous origin (e.g., cholesterol, triacylglycerols, and fatty acids), and all may be
represented in the analytical platforms [6–8]. Furthermore, the range of concentrations
of various lipids found in tissues is very large. Much of lipidomics has been concerned
with identifying which lipids are present in specific biological systems. Although most of
this work has been done by mass spectrometry, there are increasingly extensive databases
being made available for heteronuclear NMR [9,10], which complements the LC MS/MS
methods commonly used.
Metabolomics is a powerful tool for directly accessing molecular level change in
cells. With the help of stable isotope labeling, it is possible to follow the fate of individual
atoms from precursors into downstream metabolites. However, assessing stable isotope
incorporation into complex lipids, especially at low enrichment, has long been a challenge
due to the complexity of lipid structures and the vast number of lipid species [11,12].
Nevertheless, modern mass spectrometers are capable of resolving different isotopologues
in stable isotope experiments designed to assess lipid turnover in a wide variety of bi-
ological systems including tracer studies in vivo [13–19]. Furthermore, lipid synthesis
involves multiple metabolic pathways: both fatty acids and cholesterol derived from Ac-
CoA (Acetyl Coenzyme A) units but in separately regulated pathways, and the glycerol
and headgroup subunits of the glycerolipids, involve other pathways such as glycolysis
(for glycerol) and amino acid synthesis or uptake (e.g., serine) (cf. Figure S1). Assessing
the relative importance of these different pathways and nutrient sources requires stable
isotope tracing [20].
Cancers exhibit enhanced nutrient utilization and metabolic reprogramming [21–27].
As the metabolism is a complex network of coupled chemical reactions that transfer
substructures of molecules, the metabolite substructures must be tracked. Stable isotope
resolved metabolomics (SIRM) distinguishes pathways, functions, and even chemically
identical metabolites by tracking the provenance of substructures via NMR [28]. Beyond
pathways, the metabolic networks can be tracked through multiplexed SIRM (mSIRM)
experiments [29] which requires higher instrument performance to accommodate its needs.
NMR-based SIRM measurements provide information about positional labeling due
to metabolic activity, and thus about pathway utilization by cells under different condi-
tions [23]. This is accomplished by administering metabolic tracers with stable isotope
labels to cell or tissue cultures or whole organisms, including rodents and human subjects.
We use both multinuclear NMR and UHR-MS (UltraHigh Resolution Mass Spectrometry)
to analyze multi-elemental isotopologues [29,30]. Although stable isotope tracing has
been widely used for polar metabolites, it has not been extensively applied to lipidomics,
which is almost exclusively studied by mass spectrometry [13,20,31–33]. Furthermore, with
some exceptions, much of the MS-based lipid tracing has used deuterium, such as the
incorporation from heavy water in physiological experiments [19,33]. Although NMR is
generally much less sensitive than MS, and the resolution of lipid species is low in NMR,
there are global features of lipid mixtures than are more readily accessible by NMR than by
MS, especially in the context of 13C metabolic tracing [20,34,35]. There has been increasing
interest in using NMR with stable isotope tracing for lipid analysis, in a diverse range of
settings [36–40]. The use of a 2H or 13C stable isotope tracer or a combination of both for
NMR analysis to study de novo lipogenesis has been reported [40,41]. However, direct 2H
or 13C detection have low sensitivity, so it is very time-consuming to acquire high-quality
spectra compared with 1H detection. Although direct 13C detection observes non-protiated
positions (e.g., carbonyl and quaternary carbons), and generally there is higher resolution,
proton detection can be up to 32 times as sensitive as direct 13C detection, where a gated
decoupling experiment is used for quantitative analysis, thus requiring either more than
an order of magnitude less material or up to three orders of magnitude less time for the
same signal-to-noise ratio. Similarly, 2H has poorer resolution and is up to 100 times less
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sensitive than 1H, though, because of the short T1 value, it may be of comparable sensitivity
to 13C [41].
In particular we compare results using TOCSY (Total Correlation Spectroscopy) and 1D
1H{13C}-HSQC (Heteronuclear Single Quantum Coherence spectroscopy) for determining
13C incorporation into different metabolic subunits of complex lipids (glycerol versus
fatty acyl chains in glycerolipids, and methyl groups of cholesterol) in an unfractionated
mixture. This study utilizes the methyl resonances of phosphatidyl choline (PC) as an
internal reference, which has a known natural abundance level of 13C, to normalize other
lipid subgroup signals in both 1D proton and 1D HSQC spectra to determine the fractional
enrichment. The TOCSY spectra are used for two purposes: (i) signal assignment and
(ii) independently determining 13C enrichment, at least for the glycerol subunits.
TRAP-1 (TNF (Tumor Necrosis Factor) Receptor Associated Protein-1) is a mitochon-
drial chaperone protein of the heat shock family. It has been reported that TRAP-1−/− mice
showed a reduced incidence of age-associated pathologies, including obesity, inflammatory
tissue degeneration, dysplasia, and spontaneous tumor formation [42]. This was accompa-
nied by a global upregulation of oxidative phosphorylation and glycolysis transcriptomes,
causing deregulated mitochondrial respiration, oxidative stress, impaired cell proliferation,
and a switch to glycolytic metabolism in vivo. These data identify TRAP-1 as a central
regulator of mitochondrial bioenergetics, and this pathway could contribute to metabolic
rewiring in tumors [42]. Here we illustrate how high resolution heteronuclear NMR can
complement MS and can be used to determine the levels of labeling in different subunits of
intact lipids on a global scale, using PC3 (prostate cancer) and UMUC3 (bladder cancer)
cells with or without TRAP-1 knockout, grown in the presence of uniformly 13C-labeled
([U-13C])- glucose or [U-13C]-glutamine.
2. Results
2.1. NMR Analysis
High resolution tandem mass spectrometry can provide very detailed information
about the particular lipid species present in a complex mixture, and thus about the label-
ing patterns of metabolic subunits. However, that approach is less suited for addressing
questions about lipids in bulk including the major metabolic subunit labeling (e.g., glyc-
erol versus acyl chains) and the relative abundances of classes of complex lipids (e.g.,
phosphatidylcholines and cholesterol). We have developed a way to quickly estimate
the incorporation of 13C into different subunits of complex lipids in bulk by NMR. Using
cellular phosphatidylcholine lipids (PCs) as an internal standard, we can quickly assess
the 13C incorporation levels into different functional groups of unfractionated lipids. Since
mammalian cells do not have the ability for de novo synthesis of choline, all the choline
methyl groups inside the cells are at natural abundance (1.07%). The ratio of peak in-
tensities of other species to that of PC methyl peaks in the proton spectrum represents
the unlabeled species and that from the HSQC spectrum reflects the labeled species. The
relations between these two ratios gives the 13C fractional enrichment of the specific groups.
Furthermore, by comparing the intensities of the choline peaks with those of glycerol or
cholesterol, the relative amounts of these classes of lipids can be estimated.
2.2. 13C Incorporation from Glucose and Glutamine by 1H NMR
Two different cell lines (PC3 and UMUC3) were treated with either [U-13C]-glucose or
[U-13C]-glutamine tracers (U = uniformly labeled). The cellular lipids were extracted and
analyzed by 1H NMR for maximal sensitivity. However, due to the overall low fraction
of 13C lipids species and severe overlapping with other signals, the 13C satellite peaks
of those incorporated species are difficult to quantify. Figure 1 shows a 1D 1H spectrum
of PC3 lipids grown in the presence of [U-13C]-glucose. The acyl chains are observed in
the region from 0.8 to 3 ppm (Figure 1A), including the terminal methyl groups, the bulk
CH2, and the resolved protons attached to C2, C3, and C4. In addition, cholesterol methyl
resonances are well resolved at 0.7 and 1 ppm. 13C satellites are difficult to discern in these
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spectra due to their low intensity as well as overlapping with other signals. The choline
and ethanolamine headgroup resonances and those of the glycerol backbone subunit of the
phospholipids are between 3 and 5 ppm (Figure 1B). Only one of the glycerol head group
C1 carbon satellites is easily observed in the proton spectrum (Figure 1B). The C3 carbon
satellite is visible but hard to quantify, as it overlapped surrounding peaks.
To determine the labeling patterns more clearly, we recorded two dimensional TOCSY
and HSQC spectra, which showed clear cross peak patterns and appropriate chemical
shifts for all the C1, C2, and C3 positions of the glycerol subunit in glycerolipids [44]. The
TOCSY spectra (Figure 2A,B boxes) showed reproducible and substantial 13C labeling in
the glycerol subunits (>50%, Table 1) [34,35,45] of extracts of cells grown in the presence
of [U-13C]-glucose, which were absent in the extracts of cells grown on unlabeled media
or media containing [U-13C]-glutamine. The HSQC spectrum (Figure 2C) confirmed the
assignments of the peaks observed in the 1D and TOCSY spectra. The 13C satellites in
the TOCSY spectrum can be volume integrated to provide the positional (isotopomer)
enrichment in the glycerol subunits. The TOCSY spectra also show some resolution of the
acyl chains, most notably at the sites of unsaturation, the terminal methyl group, and at the
C2,C3,C4 positions of the acyl chains (Figure 2A). However, in these cells, the labeling of
the acyl chains was low, such that the integration of the TOCSY and 1D proton spectra was
not reliable if not impossible. We then turned to the assessment of 13C incorporation using
1D 13C{1H}-HSQC spectra, as described in the Methods.
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Figure 1. 1D NMR spectra of lipids extracted from UMUC3 WT (wild type) cells. Lipids were extracted from cells grown
in the presence of [U-13C]-glucose, dried, and redissolved in d4-methanol. NMR spectra were recorded at 15 ◦C with 1D
1H-NMR collected with 512 transients and an acquisition time of 2 s with 14,368 points using a spectral width of 12 ppm
with a relaxation delay of 4.0 s. The data were linear predicted and zero filled to 65,536 data points and well resolved peaks
are labeled as shown according to the literature [43] and our in-house standard database. 1H PRESAT spectrum. (A) Upfield
region showing acyl chains and cholesterol resonances. The vertical scale is expanded to show the peaks that are small
compared with that of the bulk CH2 resonance at 1.32 ppm. (B) Lower: downfield region showing glycerol and headgroup
region; inset shows the double bond and glycerol C2 region. Assignments are displayed in the figure. The sharp resonances
(asterisks) at 1.4 and 2.2 ppm are from BHT.
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Figure 2. 1H TOCSY and 1H{13C}-HSQC spectra of lipids extracted from PC3 cells grown on [U-
13C]-glucose. TOCSY spectra were recorded at 15 °C, 14.1 T with acquisition tines of 1 s in t2, 0.04 s 
in t1 with a DIPSI2 (Decoupling In the Presence of Scalar Interactions) spin lock of 50 ms mixing 
time, and a B1 field strength of 6.5 kHz. The 2D HSQC spectrum was acquired with 12 ppm in the 
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ms in F1. Adiabatic decoupling was applied and a transfer delay of 3.425 ms corresponding to 146 
Figure 2. 1H TOCSY and 1H{13C}-HSQC spectra of lipids extracted from PC3 cells grown on [U-13C]-glucose. TOCSY
spectra were recorded at 15 ◦C, 14.1 T with acquisition tines of 1 s in t2, 0.04 s in t1 with a DIPSI2 (Decoupling In the Presence
of Scalar Interactions) spin lock of 50 ms mixing time, and a B1 field strength of 6.5 kHz. The 2D HSQC spectrum was
acquired with 12 ppm in th proto dimension and 200 ppm in the carbon dimension. Acquisition time is 0.25 s in F2 and
8.5 ms in F1. Adiabatic decoupling was applied and a transfer delay of 3.425 ms corresponding to 146 Hz was set for an
optimal one bond CH coupling. (A) Full spectrum showing different subgroups of complex lipids. (B) Downfield region
expansion showing cross peaks and 13C satellites in the glycerol subunits, and cross peaks of the choline headgroup. Green
dashed boxes indicate the doubly labeled adjacent carbons in the glycerol backbones. (C) HSQC spectrum confirming the
assignments from the PRESAT and TOCSY spectrum.
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Table 1. Summary of fractional 13C level in lipid subgroups from both cell lines (WT: wild type as well as KO: knock out) determined by NMR. Lipid subgroup 13C levels were calculated
as described in the text (Equations (1) and (2)) and are presented as % of the total carbon at different position in the lipids (mean ± standard deviation for triplicate labeled samples, only
one unlabeled sample in each group).
Groups
UMUC 3 PC3
Glc Gln Unlabeled Glc Gln Unlabeled
WT KO WT KO WT KO WT KO WT KO WT KO
Acyl CH2 2.7 ± 0.43 3.0 ± 0.60 2.8 ± 0.37 3.9 ± 0.39 1.73 1.28 3.8 ± 0.24 5.4 ± 0.29 1.8 ± 0.20 1.45 ± 0.07 1.0 0.86
Methyl–
CH2–CH3
3.1 ± 0.15 2.45 ± 0.16 2.7 ± 0.33 2.3 ± 0.29 1.81 2.18 2.6 ± 0.07 3.1 ± 0.07 1.5 ± 0.01 1.5 ± 0.11 0.94 1.08
Acyl
CH2–CO
5.2 ±0.26 4.9 ± 0.42 3.9 ± 0.21 3.7 ± 0.18 0.81 1.34 7.4 ±0.28 8.5 ± 0.52 3.2 ± 0.03 3.1 ±0.07 0.94 1.08
Acyl
CO–CH2–CH2
3.1 ± 0.19 2.5 ± 0.05 2.3 ± 0.09 2.5 ± 0.33 1.24 0.39 3.9 ± 0.14 5.5 ± 0.22 2.0 ± 0.06 2.1 ± 0.20 0.95 0.91
Glyceryl–C1H 59.3 ± 0.90 52.8 ± 1.28 nd a nd nd nd 62.3 ± 1.17 65.2 ± 0.88 nd nd 0.80 nd
Glyceryl–C2H 41. 9 ± 0.55 33.4 ± 0.41 nd nd nd nd 48.9 ± 1.70 53.0 ± 2.93 nd nd 1.45 nd
Glyceryl–C3H 61.5 ± 6.81 50.4 ± 3.22 1.84 2.17 1.84 1.1 67.1 ± 0.41 72.8 ± 1.63 2 ± 0.08 2.1 ± 0.41 1.76 1.87
Acyl
=CH– 1.2 ± 0.11 1.3 ± 0.03 1.1 ± 0.07 0.91 ± 0.07 0.88 1.04 0.90 ± 0.08 0.99 ± 0.06 0.88 ± 0.04 0.97 ± 0.03 0.83 0.79
Acyl
=CH–CH2–CH=
0.97 ± 0.18 1.11 ± 0.14 1.03 ± 0.22 1.08 ± 0.14 0.97 0.89 0.77 ± 0.05 0.94 ± 0.11 0.78 ± 0.04 0.85 ± 0.05 0.89 0.70
Acyl
CH2–CH2–CH=
2.2 ± 0.07 1.5 ± 0.03 1.8 ± 0.15 1.5 ± 0.06 0.74 0.45 1.8 ± 0.54 2.0 ± 0.06 0.96 ± 0.04 1.10 ± 0.06 0.93 0.90
Chol–18 5.5 ± 0.33 4.6 ± 0.04 4.4 ± 0.69 4.0 ± 0.36 1.46 nd 3.6 ± 0.08 3.2 ± 0.23 2.1 ± 0.10 1.9 ± 0.09 1.54 1.38
Chol–19 3.8 ± 0.24 3.6 ± 0.11 2.6 ± 0.14 3.3 ± 0.15 0.68 nd 2.7 ± 0.04 2.1 ± 0.07 1.7 ± 0.08 1.4 ± 0.16 0.85 1.36
a not determined.
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2.3. Determination of 13C Incorporation from Glucose and Glutamine by 1H{13C}-HSQC
The 1D HSQC spectra of the lipid extracts from PC3 and UMUC3 cells grown in the
presence of either [U-13C]-glucose or [U-13C]-glutamine are compared with the same cells
grown in the presence of unlabeled glucose in Figure 3 and Figure S3. As Figure 3 shows,
the extracts of cells grown on [U-13C]-glucose show much more intense glycerol peaks than
either the [U-13C]-Gln or unlabeled samples. Revealingly, the various acyl chain peaks
are also more intense in the glucose sample indicating significant 13C incorporation into
the fatty acyl chain. The actual 13C incorporation into each position was calculated, as
described in the Methods section. From Table 1, it is clear that, in both cell lines grown on
13C-glucose, the glycerol head groups were heavily enriched (over 50%), since they derive
from dihydroxyacetone-3-phosphate, which is an intermediate of glycolysis. These agreed
very well with the integration from the carbon satellite peaks of these groups from proton
spectra as well as 2D TOCSY spectra. We quantified the central unlabeled peaks as well as
the 13C satellite peaks from the TOCSY spectrum (cf. Figure 2A) of one WT PC3 sample
and found that the glycerol C1 group 13C enrichment was 60.31%, the C2 group enrichment
was 51.26%, and the C3 group enrichment was 59.57%, respectively, and these are very
close to the figures calculated from 1D HSQC for this particular sample (62.7%, 50.4%, and
66.7%). Furthermore, the natural abundance 13C level averaged over all unlabeled samples
and positions was 1.08 ± 0.37% (Table 1), which agrees well with the expected value of
1.07%. This indicates that our method of estimating the fractional enrichment from the 1D
HSQC is viable. For comparison, we also recorded a direct observe 13C spectrum of the
lipid extract of PC3 cells grown in the presence of [U-13C]-glucose, which required 18 h
acquisition for a comparable signal-to-noise ratio to the 1D HSQC (Figure S4).
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glutamine, or no tracer. The spectra were recorded with 13C adiabatic decoupling during the acquisition time of 0.25 s
for 1024 scans (34 min acquisition). The spectral width was set at 12 ppm the same as the proton spectrum and recycle
delay was set to 1.75 s. A total of 1796 data points were collected and zero filled to 4096 points with a 4 Hz line-broadening
exponential. [U-13C]-Glucose tracer samples in both cell types showed 13C incorporation into various functional groups,
with glycerol backbones as the most heavily labeled groups. In contrast, [U-13C]-glutamine labeled samples only showed
incorporation mainly into bulk acyl-chains as well as C2, C3 positions on the fatty acids, indicating the main contribution of
de novo fatty acid synthesis. The 1D HSQC spectra shown are normalized to cell numbers.
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We used the same method to determine the 13C incorporation into UMUC3 cells. At
the glycerol-C1 group, we found 59.3 ± 0.9% enrichment from [U-13C]-glucose in the wild
type cells and 52.8% ± 1.28% in the UMUC3 knockout cells, and not different from natural
abundance for the [U-13C]-Gln samples (Table 1). The 13C labeling of the glycerol carbons
was similar to the wt PC3 cells (62.3 ± 1.2%), but slightly lower than in the PC3 KO cells
(65.2 ± 0.88%). This indicates a high fraction of the glycerolipid pool turnover using G3P
newly synthesized from glucose. In comparison, labeling of the bulk CH2 groups in the
lipid fatty acid chains was much lower, around 4–5%. Terminal methyl groups showed
around 2–3% labeling, indicating that the ab initio de novo synthesis of fatty acid chains
are relatively low in these cells. Meanwhile, the C2 and C3 groups which are next to the
carboxylate end of the acyl chains, were more highly labeled (7–9% for C2 and 4–6% for C3)
due to extension with newly synthesized [46] AcCoA from glycolysis and PDH activity.
In cells grown in the presence of [U-13C]-Gln and unlabeled glucose the glycerol
groups showed no significant labeling (i.e., close to natural abundance) (Figure 4, Table 1),
indicating little de novo gluconeogenesis in these cells, as previously observed for breast
cancer cells [35]. However, the fatty acid chains were enriched to around 3–4% due to
the cytosolic AcCoA generated from citrate that may arise from reductive glutamine
metabolism and transported out of the mitochondria [47–49] or exchange flux [49].




Figure 4. 1D HSQC spectra of the lipid extracts from UMUC3 cells grown in the presence of [U-13C]-glucose, [U-13C]-
glutamine and unlabeled glucose. UMUC3 cells were grown and extracted, then prepared for NMR as described in the 
Methods section. The HSQC acquisition parameters were as described in Figure 3. 
In [U-13C]-glucose tracer experiments, the glycerol group fractional enrichments were 
similar in both PC3 and UMUC3 cell lines. In contrast, the bulk CH2 in the PC3 cells were 
more enriched than that in the UMUC3 cells. Both C2 and C3 of the fatty acids chain were 
more highly enriched in PC3 cells compared with UMUC cells, indicating a more active 
fatty acid extension reaction in PC3 cells. In the [U-13C]-glutamine tracer experiments, the 
labeling in the various fatty acid groups was in general lower in PC3 than in UMUC3, and 
in both cases was not much above natural abundance. 
For the labeled samples, the cholesterol 18 and 19 methyl groups showed 13C enrich-
ments above a natural abundance of 4–5% in the UMUC3 cells, and these were lower (2–
3%) in the PC3 cells (Table 1), indicating a higher flux of AcCoA into cholesterol synthesis 
in UMUC3 cells. 
2.4. Estimation of Lipid Distributions from NMR 
In addition to measuring the 13C incorporation into different metabolic subunits (e.g., 
glycerol, acyl chains, and cholesterol), the NMR spectra also provide information about 
the distribution of classes of lipids. For example, the relative amount of PCs in the total 
glycerolipid pool could also be estimated from the ratio of the glycerol group to the cho-
line methyl group. Thus, the glycerol resonances represent all glycerol lipids, whereas the 
choline NMe3+ resonance at 3.21 ppm represents the total PC levels. From the unlabeled 
samples and the samples grown in the presence of [U-13C]-Gln, we estimate that the PC/to-
tal GPL was 55.2% ± 5.6% for WT PC3 and 39.3% ± 6.1% for UMUC3. 
Using the resolved methyl resonances of cholesterol at 0.71 and 1.02 ppm in both 1H and 
HSQC spectra (Figure 2), we determined the ratio of lipid choline to cholesterol in 1D 1H 
Figure 4. 1D HSQC spectra of the lipid extracts fro l r n in the presence of [U-13C]-glucose, [U-13C]-
glutamine and unlabeled glucose. U UC3 cells ere gro n and extracted, then prepared for NMR as described in the
Methods section. The HSQC acquisition parameters were as described in Figure 3.
In [U-13C]-glucose tracer experiments, the glycerol group fractional enrichments were
similar in both PC3 and UMUC3 cell lines. In contrast, the bulk CH2 in the PC3 cells were
more enriched than that in the UMUC3 cells. Both C2 and C3 of the fatty acids chain were
more highly enriched in PC3 cells compared with UMUC cells, indicating a more active
fatty acid extension reaction in PC3 cells. In the [U-13C]-glutamine tracer experiments, the
labeling in the various fatty acid groups was in general lower in PC3 than in UMUC3, and
in both cases was not much above natural abundance.
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For the labeled samples, the cholesterol 18 and 19 methyl groups showed 13C enrich-
ments above a natural abundance of 4–5% in the UMUC3 cells, and these were lower (2–3%)
in the PC3 cells (Table 1), indicating a higher flux of AcCoA into cholesterol synthesis in
UMUC3 cells.
2.4. Estimation of Lipid Distributions from NMR
In addition to measuring the 13C incorporation into different metabolic subunits (e.g.,
glycerol, acyl chains, and cholesterol), the NMR spectra also provide information about
the distribution of classes of lipids. For example, the relative amount of PCs in the total
glycerolipid pool could also be estimated from the ratio of the glycerol group to the choline
methyl group. Thus, the glycerol resonances represent all glycerol lipids, whereas the
choline NMe3+ resonance at 3.21 ppm represents the total PC levels. From the unlabeled
samples and the samples grown in the presence of [U-13C]-Gln, we estimate that the
PC/total GPL was 55.2% ± 5.6% for WT PC3 and 39.3% ± 6.1% for UMUC3.
Using the resolved methyl resonances of cholesterol at 0.71 and 1.02 ppm in both 1H
and HSQC spectra (Figure 2), we determined the ratio of lipid choline to cholesterol in
1D 1H spectra. For the unlabeled samples, we estimated the choline/cholesterol ratio as
1.85 ± 0.24 for UMUC3 WT and 1.65 ± 0.05 for PC3 WT.
The TOCSY spectra (Figure 2B) also show the presence of other headgroups, notably
ethanolamine, which is therefore relatively abundant. Comparing the intensity of the
methylene peaks from PE (Phosphatidylethanolamine) head groups and PC headgroup
peaks showed a PC/PE ratio of 1.2 in the PC3 WT cells. However, we observed no
significant intensity from PS in these samples, though such lipids were observed in mass
spectra of the samples, indicating that this class of lipids is at low overall abundance.
3. Discussion
NMR has been applied for lipidomics analysis, and with some isolated peaks in the
proton spectrum, the quantification of certain types of lipids can be made from a series of
equation manipulations in standard mixtures or lipid hydrolysis products [50,51]. However,
for crude lipid extracts, due to the complexity of the lipid structure and species, few NMR
methods have been applied this type of study, let alone with isotope tracers. Here we
report a different perspective to apply NMR for lipidomics studies. Instead of quantifying
individual lipid species, we investigated the overall substructure of the lipid functional
groups and traced the incorporation of 13C from [U-13C]-glucose or [U-13C]-glutamine.
PC is the most abundant lipid class in mammalian cells [52] and is highest in cells
that do not contain significant lipid droplet stores [53]. It may also be impacted in certain
cancers [54]. We have used 1D 1H NMR and 2D TOCSY and HSQC to characterize the
metabolic labeling of abundant lipid classes in two cancer cell lines. From the TOCSY
spectra, we were able to determine the 13C incorporation into the glycerol subunits with a
CoV of <5% (at a labeling level of >50%). For lower level incorporation, where the HSQC
spectra were used, the estimated CoV were <10% for the acyl chains and 5–7% for the
cholesterol methyl groups. For the unlabeled samples, the 13C level at each site should be
the natural abundance level, i.e., 1.07%. Table 1 shows that, whereas most peaks are close
to the expected value, with an overall CoV of 5–10%, there are a couple of outliers, which
likely reflect integrations at low total abundance and/or signal overlap. These values place
a lower limit on estimating enrichment of 2–4%.
In both cell lines, the glycerol subunit, which is predominantly PC, was heavily labeled
from glucose but not from glutamine. In contrast, the acyl chains and cholesterol were
much less extensively labeled, similar to HEK293 cells [34] or MDAMB231 cells [35] but
unlike in some other cell lines [20,35,46,55,56]. The high enrichment in the glycerol subunit
indicates substantial de novo lipid synthesis using glucose via DHAP/G3P, but relatively
little glucose or Gln contributed to the AcCoA pool, as the acyl chains and cholesterol
were enriched about one order of magnitude less. As the cells proliferate and make new
lipids, either these cells recycle fatty acids (such as from internal lipid stores [34]), take up
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fatty acids from the medium [57,58], or use carbon sources other than glucose or Gln to
generate AcCoA.
In general, PC comprises 40%–50% of total phospholipids, while PE comprises around
15%–25% in mammalian cells and subcellular organelles [52]. The PC fraction in the PC3
wild type cells was 55.2% ± 5.6% and 53.8 ± 7.3% for KO cell lines, whereas the enrichment
was 39.2% ± 6.1% for UMUC3 WT cells and 49.4% ± 15.1% for KO cells.
The cholesterol/GPL ratio was also estimated from the ratios of labeled and unlabeled
free cholesterol to phosphatidylcholine. According to our calculations, the total ratios of
phosphatidylcholine to free cholesterol was 1.65 ± 0.05 for WT PC3 cells and 1.47 ± 0.08
for KO PC3 cells, whereas these ratios were 1.85 ± 0.24 and 1.62 ± 0.15 for WT and KO
UMUC-3 cells, respectively. This compares with the PC/free cholesterol ratio in mouse
livers of 2.5–2.7 on a regular diet and 1.0–1.1 on a high cholesterol diet [59].
PC can be generated from the CDP-choline pathway or PE N-methyltransferase
(PEMT) pathway, where PE is converted into PC by three methylation reactions. Mouse
hepatic PC/PE ratio between 1.5 and 1.8 maintains membrane integrity, while a ratio of <1
leads to membrane destruction [60]. Quantification of cross peaks of head groups of PC
and PE from the TOCSY spectrum showed the PC/PE ratio is around 1.2 for PC3 WT cells.
We did not observe significant amounts of PS in either 1D or 2D NMR, indicating the low
abundance of PS in these two types of cancer cells. We also observed insignificant labeling
of the PE head group, suggesting that glucose was not a major source of serine carbon in
these cells.
4. Materials and Methods
Wild type PC-3 (prostate cancer) and UMUC3 (bladder cancer) cells were purchased
from ATCC (American Type Culture Collection, Manassas, VA, USA), and the TRAP-
1 KO version was generated in-house in the laboratory of Dr. L. Neckers. Cells were
seeded in 10 cm dishes at 3 million cells per dish, incubated in either a DMEM (Dulbecco’s
Modified Eagle’s Medium) medium containing 25 mM [U-13C]-glucose, 2 mM unlabeled
Gln (in triplicate), 25 mM unlabeled Glc + 2 mM [U-13C,15N]-Gln and 10% dialyzed FBS (in
triplicate), or unlabeled media (single plate), at 37 ◦C in a 5% CO2 atmosphere, RH > 90%
for 24 h (approximately one cell doubling). After incubation, the medium was aspirated,
and the cells (6 million per plate) were washed twice with ice cold PBS and then quenched
on the plate as previously described [3]. Metabolites were extracted using a modified
Folch method [61], and the organic layer was dried in a vacufuge at room temperature and
resuspended in 2:1 (v/v) chloroform/methanol + 1 mM Butylated HydoxyToluene (BHT)
for storage at −80 ◦C prior to NMR analysis [3].
NMR analysis: Lipid samples were dried again prior to the NMR experiment and
reconstituted in 100% methanol-d4 (CIL, Tewkesbury MA) and loaded into 3 mm matched
Shigemi NMR tubes. 1-D proton (PRESAT), TOCSY (zTOCSY) and 1H{13C} HSQC spectra
(gHSQCAD) were recorded with adiabatic decoupling at 15 ◦C on an Agilent (Santa Clara,
CA, USA) DD2 14.1 T NMR spectrometer equipped with a 3 mm inverse triple resonance
cold probe. Spectra were referenced to the methanol resonance at 3.3 ppm and the phos-
phatidyl choline NMe3+ resonance at 3.21 ppm. 1D 1H spectra were recorded with an
acquisition time of 2 s with continuous weak irradiation of the HOD peak during a re-
laxation delay of 4 s and 512 transients (52 min). TOCSY spectra were recorded with
acquisition times of 1 s in t2 and 70 ms in t1 with an isotropic mixing time of 50 ms at
a B1 field strength of 6.6 kHz using DIPSI-2, with 8 transients per t1 increment and 512
complex pairs (4.6 h acquisition). Assignments and isotopomer distributions in 1H NMR
were determined as previously described [20,35,36,62]. HSQC spectra were recorded with
adiabatic 13C decoupling during a 0.25 s acquisition time, with a relaxation delay of 1.75 s
and 1024 transients (34 min acquisition). The 1D 13C gated decoupler experiment was
recorded in 18 h using the X-coil of the 3 mm probe as the HSQC, with an acquisition time
of 1 s, a relaxation delay of 1 s, and 32,000 transients.
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Isotopomer distributions were also determined from 1D 1H{13C}-HSQC by compar-
ing the relative integrals (areas) of peaks with that of the choline N(CH3)3 resonance at
3.21 ppm, which is exclusively natural abundance, with the same ratio in an unlabeled sam-
ple. A higher ratio indicates 13C incorporation, and the enrichment is directly proportional
to the ratios in the two sample types.







where A(13C) is the area of the 13C satellites, and A(12C) is the area of the unlabeled peak.
For low level enrichments, the positional 13C fractions for each lipid group by HSQC,












where A(13CX) HSQC and A(13Cc) HSQC are the areas of peak X and the choline methyl
resonances in HSQC spectra, and A(12CX) 1H and A(12Cc) 1H are the areas of peak X and
the choline methyl resonances in the 1H PRESAT spectrum.
In the PC/total lipids or PC/cholesterol ratio calculation, we used the glycerol-C3H
and cholesterol-18 methyl group peak as representative signals. Since their enrichment
levels are different (PC is only natural abundance), both 13C and 12C species contribute to
the total ratio but at different weights. Here, x represents either cholesterol or glycerol-C3H,
while c represents choline.










Area notations are the same as described above.
5. Conclusions
The methods described here provide both high resolution mapping of complex lipids
without chromatographic separation and a direct way of generating an overview of 13C
incorporation into bulk lipid molecules, which can be utilized as a standalone approach or
to complement targeted mass spectrometry-based lipidomics workflows [45]. Further, with
a detection limit as low as 2% with a COV of <10% by HSQC, it provides very valuable
metabolic information that other techniques cannot easily generate. HSQC is sufficient to
provide both high and low labeling isotopomer quantification. The TOCSY spectra are
useful for validating peak assignments, for improved resolution and satellite quantification
when 13C incorporation is relatively high (cf. the glycerol subunits in the present study),
and for cross-validating HSQC analyses under those conditions. The sensitivity advantage
of proton detection over 2H or 13C enables estimation of low (<10%) 13C enrichment or
with much smaller quantities of material.
Although we demonstrated the method here using 2D cell culture, we and others
have successfully applied the SIRM approach to a variety of different systems, including
3D spheroids, mouse models, and human subjects. Introducing a label via injection or
diet is straightforward [35,62,64–66], and the extraction procedures for tissues are also
well established. From then on, the analysis is the same as for cells. We note also that,
with the amount of material used in this study, the necessary 1H and 1D HSQC spectra
can be recorded in about 1.3 h per sample using a cryoprobe, implying an approximate
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throughput of up to 20 samples per day under automation, without destruction of the
samples. In contrast, direct observation of 13C using a cryoprobe would have a throughput
of 1–2 samples per day.
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